Session: Poster Session B Abstract title:Combination immunotherapy with an albumin-binding interleukin-12 fusion protein that extends cytokine half-life, targets the tumor microenvironment, and ...

The trial will explore the effects of higher doses of ACD856, building on the drug’s established safety profile.

Tiziana Life Sciences (TLSA) announced the dosing of an additional four patients in its Intermediate Size Patient Population Expanded Access ...

Anavex Life Sciences Corp.'s stock rises 50% as EMA reviews Alzheimer's drug blarcamesine. Click for my updated look at AVXL stock and why I have upgraded it.

The Fast Track designation is supported by data from the open-label phase 1 SNK01-MX04 trial, as well as preliminary data from the phase 1 cohort from the phase 1/2a SNK01-AD01 trial.

Lipella's LP-310 Phase 2a trial showed strong efficacy and safety for oral lichen planus. The company plans a Phase 2b trial ...

Aclaris' stock has dropped nearly 70% since September 2023, reflecting its history of failures and dissipations. Explore more ...

About LP-310 LP-310 is an innovative oral rinse formulation of LP-10 (tacrolimus), developed to address OLP. Designed to provide localized therapeutic effects while minimizing systemic exposure, ...

The funding will support the initiation of phase 2a clinical trial of APAC for peripheral arterial occlusive disease/chronic limb threatening ischemia (PAOD/CLTI) in Finland. APAC is also poised to ...

These capsules are to be used in a forthcoming Phase 2a clinical trial targeting Parkinson’s disease. The agreement stipulates that Catalent will manufacture clinical batches of JOTROL™, a resveratrol ...